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ANALISIS FITOKIMIA DAN PENILAIAN BIOAKTIVITI EKSTRAK 
TERPIAWAI MITRAGYNA SPECIOSA DAN FARMAKOKINETIK 
MITRAGYNINA 
ABSTRAK 
 Kesan farmakologi ekstrak daun M. speciosa dan mitragynina dalam tikus telah dikaji. 
Dua kaedah analitikal kromatografi cecair prestasi tinggi KCPT-UV yang baru telah 
dibangunkan dan disahkan untuk menganalisa mitragynina dalam ekstrak daun M. 
speciosa dan plasma tikus. Kedua-dua kaedah KCPT-UV untuk matrik tumbuhan dan 
plasma menghasilkan kromatogram yang bersih, masa analisis yang pendek , kepekaan 
analisis yang baik dan berjaya diaplikasikan dalam analisi yang berkaitan. Kaedah 
KCPT-UV yang pertama telah digunakan untuk mempiawaikan ekstrak-ekstrak akues, 
metanolik dan alkaloid daun M. speciosa yang selanjutnya digunakan dalam  kajian 
antimikrobial dan  antioksidan. Kaedah analitikal kromatografi cecair prestasi tinggi 
KCPT-UV yang kedua juga menggabungkan teknik pengekstrakkan SPE untuk 
pembersihan sampel plasma telah digunakan bagi penentuan farmakokinetik  
mitragynina dalam tikus. Kandungan mitragynina dalam ekstrak alkaloid, ekstrak 
metanol dan akues masing-masing adalah 23.0, 4.4, 0.7%. Kaedah ini juga didapati 
setara dalam aplikasi penentuan mitragynin dalam rebusan daun M. speciosa yang 
diperolehi dari jalanan.  Ciri-ciri antioksidan ekstrak daun M. speciosa telah ditentukan 
dengan menggunakan ekstrak piawai. Jumlah  kandungan fenolik dalam ekstrak akues, 
alkaloid dan metanolik masing-masing adalah 66.0 mg, 88.4 mg dan 105.6 mg GAE/g. 
Ekstrak akueus, alkaloid dan metanolik M. speciosa  telah dinilai untuk aktiviti 
mikrobial bagi mikrob organisma tertentu. Kepekatan minimum rencatan ekstrak-ekstrak 
ini dengan mengunakan teknik pencairan bubur adalah dalam julat 3.12 ke 6.25 mg/mL. 
xviii 
 
Hasil kajian menunjukkan ekstrak metanolik mempunyai aktiviti antioksidan yang 
tinggi. Manakala ekstrak daun M. speciosa yang kaya dengan alkaloid ditemui lebih 
berkesan terhadap mikrob organisma yang diuji berbanding ekstrak yang lain. 
Farmakokinetik mitragynina telah dikaji pada tikus selepas administrasi oral dan 
intravenus  mitragynina. Selepas administrasi intravenus, mitragynina mempamerkan 
penyingkiran dua fasa daripada plasma dengan purata separuh hayat 2.9 ± 2.1 jam. 
Penyerapan oral mitragynina adalah perlahan, tidak tetap dan disingkirkan dengan 
jangkamasa separuh hayat 6.6 ± 1.3 jam. Nilai mutlak bioketersediaan oral mitragynina 
adalah 3.03%. Variasi yang diperhatikan dalam kajian farmakokinetik mitragynina yang 
dilaporkan dalam literasi untuk tikus adalah disebabkan oleh bioketersediaan oral 
mitragynina yang rendah dan bukan limitasi ujikaji, tepuan metabolik dan perbezaan dos 
mitragynina. 
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PHYTOCHEMICAL ANALYSIS AND BIOACTIVITY EVALUATION OF 
STANDARDIZED EXTRACTS OF MITRAGYNA SPECIOSA AND 
PHARMACOKINETICS OF MITRAGYNINE. 
 
ABSTRACT 
 
The pharmacology of M. speciosa leaf extracts and mitragynine in rats were 
investigated. Two new High Performance Liquid Chromatography Ultraviolet HPLC –
UV analytical methods were developed and validated for assay of mitragynine in M. 
speciosa leaf extracts and plasma. Both HPLC-UV method for assay of mitragynine in 
plant matrix and plasma yield a clean chromatogram, short analysis time, good assay 
sensitivity and was successfully used for their intended applications. The first HPLC-UV 
method was used to standardize water , methanolic and alkaloid extracts of M. speciosa 
leaf which was subsequently used for antimicrobial and antioxidant  studies. The second 
HPLC-UV method with SPE extraction techniques for plasma sample clean up was 
employed to determined the mitragynine pure compound pharmacokinetics in rats. The 
mitragynine (MG) content in alkaloid rich fraction, methanol extract and water extract 
were 23 , 4.4 and 0.7% respectively . The method was found equally applicable to 
determine mitragynine in decoction M. speciosa leaf (50-180µg/mL) obtained from the 
streets. The antioxidant properties of M. speciosa leaf extracts were determined using 
standardized extracts.The total phenolic content of the aqueous, alkaloid and methanolic 
extracts were 66.0 mg, 88.4, 105.6 mg GAE/g, respectively, while the total flavonoid 
were 28.2, 20.0 and 91.1 mg CAE/g respectively The aqueous, alkaloid and methanolic 
extracts were further screened for antimicrobial activity for selected microorganism. The 
xx 
 
minimum inhibitory concentrations of this extracts determined by the broth dilution 
method ranged from 3.12 to 6.25 mg/mL. The results suggest that the methanolic extract 
showed relatively high antioxidant activity whereas as for the bioactive analysis, 
alkaloid rich fraction was found to be most effective against all of the tested organisms 
in comparison to other extracts. The mitragynine pharmacokinetics was investigated in 
rats after oral and intravenous administration of mitragynine. After intravenous 
administration mitragynine demonstrated biphasic elimination from the plasma with a 
mean half-life of 2.9±2.1 h. The oral absorption of mitragynine was slow, erratic and 
eliminated with prolonged half-life of 6.6±1.3 h .The calculated absolute oral 
bioavailability of mitragynine was 3.03 %. The variations observed in previous 
pharmacokinetic studies after oral administration of mitragynine could be attributed to 
its poor bioavailability rather than to the differences in assay method, metabolic 
saturation or mitragynine dose. 
  
1 
 
CHAPTER 1 
1.0 INTRODUCTION 
Historically, plants are endowed with a good source of a wide variety of 
compounds, such as phenolic compounds, nitrogen compounds, vitamins, terpenoids and 
secondary metabolites, which are rich in valuable bioactivities, e.g., antioxidant, anti-
inflammatory, antitumor, antimutagenic, anti-carcinogenic, antibacterial, or antiviral 
activities. The World Health Organization (WHO) defines traditional medicine (TM) as 
“health practices approaches, knowledge and beliefs incorporating plant, animal and 
mineral based medicines, spiritual therapies, manual techniques and exercises, applied 
singularly or in combination, to treat, diagnose and prevent illnesses or maintain well-
being” (WHO, 2002).  
Malaysia has a great potential to develop her abundant natural resources into 
herbal products as there are about 550 genera of tropical plants, containing over 1,300 
species possessing medicinal values. This has drawn chemists, biochemist, and 
pharmaceutics interests to play an important role in discovering and developing new 
drugs, with the hope of more efficacy and no side effects as in most modern drugs. 
Among the promising medicinal plants that received more attention quite recently for its 
narcotic-like effects when smoked, chewed or taken as a suspension is M. speciosa 
(Macko et al., 1972; Perry, 1980; Jansen and Prast, 1988; Matsumoto et al., 1996 
;Tsuchiya et al., 2002). It is known as “Biak” and “Ketum” in Malaysia and as “Kratom” 
in Thailand. “Ketum” use is illegal in various countries including Thailand and 
Malaysia.  
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It is an offence under the Poisons Act 1952 to possess and sell ketum leaves in 
Malaysia (Report of Narcotic Control Board, 2008). Since 1946 Thailand has legislated 
this plant. Australia also banned the ownership of this plant in 2005 (Report of Narcotic 
Control Board, 2008). However free accessibility and information of kratom widely over 
the Internet has fascinated many Westerners to exploit the plant as self-treatment in 
opioid withdrawal and pain management. (Boyer et al., 2007). In Malaysia it is 
consumed both in unadulterated and adulterated form by mixing it with cough mixtures, 
traditional herbs and even synthetic pyrethroid from mosquito coils to add zest to the 
concoction (Bothipon, et al., 2009). Adulterated decoction of M. speciosa leaves known 
locally as “ketum juice” packed in plastic bottles or packets are found in the streets 
particularly in the northern region of Peninsular Malaysia. In this region “ketum juice” is 
consumed by addicts as a substitute of more expensive opiates to manage withdrawal 
symptoms. Initially the barks and leaves of this plant were seen to be a potential cure for 
opium habits and the leaves were suggested as opium replacement (Shellard, 1974).  
Besides its opium like effect several side effects have been reported among 
ketum users such as nausea, vomiting, and quiver (Grewal, 1932a). Lengthened sleep, 
hyperpigmentation, loss of weight and anorexia are symptoms for chronic users. 
(Suwanlert, 1975). Other side effects, have been noted such as mouth dryness, 
constipation, diuresis, dark and small stools, weight loss and loss of appetite (Perry, 
1980). While “ketum” was used for this reason, there are claims in Thailand that “ketum 
juice” was primarily used to increase physical endurance and work capacity 
(Assanangkornchai et al.,2006; Suwanlert, 1975; Vicknasingam & Narayanan, 2009). 
There are study reports on the medicinal use of M. speciosa leaves such as antitussive, 
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anesthetic, antinociceptive, stimulant, analgesic and narcotic-like M. speciosa leaves 
(Takayama, 2004; Watanabe et al., 1992 Tsuchiya et al., 2002; Tohda et al., 1997; 
Thongpradichote et al., 1998). In addition to this, (Burkill, 1936) documented other uses 
of ketum as a wound healer and cure for fever. It stated that the pounded leaves are 
applied to wounds and also on enlarged spleen. (Burkill, 1936). To date no research on 
antimicrobial and antioxidant properties of the M. speciosa have been documented. 
These pharmacological activities are often attributed to the alkaloids found in the leaf 
(Parthasarathy et al., 2009). Mitragynine (MG) is the dominant alkaloid and is exclusive 
to M. speciosa. 
The use of kratom as a self management to opioid withdrawal is increasing 
without proper scientific basis and currently leads to its wide abuse (Boyer et al., 2007). 
Decoction of M. speciosa leaves from various sources are constantly being abused in 
this region and their MG content is not known. It is essential to precisely determine this 
predominant alkaloid in M. speciosa leaf extracts and decoction as this would provide a 
better understanding of their pharmacological aspect in relation to the reason it is 
consumed. Thus, there is a need for the development of a simple and faster method for 
routine quantification of MG in raw material, extracts, commercial or adulterated 
products. 
Further to this the mitragynine‟s pharmacological and behavioral effects remain 
scanty scientifically and this warrants indepth pharmacological and pharmacokinetic 
studies of mitragynine in various in vivo models. For such an exploration, a quantitative 
analysis of mitragynine in biological fluids and plant extracts are very essential. Liquid 
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Chromatography Mass Spectrometry (LCMS) methods are available for analysis of MG 
especially in biological specimens and commercial products but their methodologies are 
laborious and expensive and not easily accessible. Furthermore, prior to analysis these 
methods requires complex sample clean-up and /or pre-treatments (Phillipp et al, 2009; 
De Moraes, 2009). 
Therefore in this thesis, work has been undertaken to develop a simple and rapid 
High Performance Liquid Chromatography (HPLC) analysis method for determination 
of mitragynine in biological and plant matrix. The developed and validated methods 
were used to generate the oral and intravenous MG pharmacokinetics properties in 
animal model after administration in rats. MG plasma stability and MG content in plant 
material and abuse ketum juice were also determined. As there are anonymous claims on 
the topical use of M. speciosa leaves for infected wounds the antimicrobial and 
antioxidant activities of M. speciosa leaf extracts were also evaluated scientifically. 
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Objectives 
 To develop and validate a simple and rapid HPLC-UV analysis method for 
determination of mitragynine in plant matrixes and its application for 
standardization of various M. speciosa leaf extracts for subsequent 
pharmacological studies. 
 To determine the antioxidant and antimicrobial activities of M. speciosa leaf 
using the various standardized extracts as part of our effort to scientifically 
investigate the claim that M. speciosa leaf was used in the treatment of infected 
wounds. 
 To develop a new, rapid and simple solid-phase extraction method for HPLC-UV 
determination of MG in plasma for application in stability study and mitragynine 
pharmacokinetic study in rats 
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CHAPTER 2 
2.0 Literature review 
2.1 Plant as Herbal Medicine 
Plants have an extensive record as a source of drugs for treating human illnesses. 
(Chin et al., 2006). The pharmacopoeias of Traditional Chinese Medicine (TCM), the 
European pharmacopoeias, or the medicinal plants from traditional ethnic groups are 
well documented. Ethnopharmacology approaches are used to scientifically study the 
relationship of ethnic groups, their health, and how it relates to their physical habits and 
methodology in generating and using medicines (Johns, 1990). Some researchers viewed 
the use of medicinal plants as mechanical and/or symbolic adjuvants, vehicles, or 
facilitators of other ingredient but others regard that any activity attributed to the 
composite medicine of plants that are used to treat a wide range of disorders is usually 
presumed to be due to various ingredients (Etkin, 1986). Herbs and spices have been 
used for generations to treat ailments (Tayel & Tras 2009; Yano et al., 2006). The use of 
spices as medicines raises the issue of cultural distinctions between food and medicine 
but biomedicine increasingly recognizes the importance of diet in health and disease.  
The distinction between food and medicine is therefore blurred, and a plant may 
be considered a medicine, a medicinal healthy food or a nutritious medicine 
(Etkin,1988b).This encourages the ethnophamarcologic studies to use a multicontextual 
approach to plant use and as such, research on potential bioactive chemicals in formerly 
mundane foods have increased dramatically, and terms such as “nutraceuticals”, 
“pharmafoods” and “functional foods” are now being used regularly (Etkin & Johns, 
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1998). Indian and Tibetan cultures, among several others (Etkin & Ross, 1982; Wilson, 
1977), have long identified diet as an important component of health, and as such, 
prescribes dietary modifications concurrently with medicines.  
However, Ayurvedic medicine, has long understood spices as important 
therapeutic agents (Handa, 1998) that either support primary ingredients or are primary 
constituents themselves. The World Health Organisation (WHO) has estimated that 65-
80% of the world‟s population use traditional medicine as their primary health care. 
Further to this herbal medicine or pharmaceuticals from plant origins represent the 
majority of this health care and their practice are growing especially in developing 
countries (Drew & Myers, 1997). The use of ethnomedicines which deals with the study 
of traditional medicines (e.g. Traditional Chinese Medicine, Ayurveda) or knowledge 
and practices that have been orally transmitted over the centuries has also increased in 
Western countries, as alternative medicines to treat various conditions and diseases. 
Parallel with their usage, safety concerns with such medicine has also increased and 
committees and bodies were established to tackle this safety issue. 
 In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) 
play significant roles in ensuring that herbal medicines marketed in UK are acceptably 
safe.In the U.S., safety concern on use of herbal medicines is regulated under U.S. Food 
and Drug Administration (FDA) and also a body called the National Center for 
Complimentary and Alternative Medicines (NCCAM) (Tilburg and Kaptchuk, 2008). 
European countries also have legislation in controlling the entrance of herbal medicines 
to the market as framed in their European Directive  (Steinhoff, 2002). In Malaysia the 
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safety of herbal medicines or pharmaceuticals from plants is regulated under a 
government agency, National Pharmaceutical Control Bureau (NPCB) which is also a 
WHO collaborating Centre for Regulatory Control of Pharmaceuticals. Popular belief 
has regarded that anything „natural is safe‟. Houghton stressed the issue that even in 
„predicament plant‟ (which refers to plants affecting the central nervous system), correct 
dose and use provide useful pharmaceuticals (Houghton, 2003).  
As most of the time herbal medicines are supplied as dietary supplements or 
without prescription, they should be used with caution, as many common herbal 
medicines used in irregular, high doses or in combination with other medications, may 
pose toxic effects. The toxic effects can range from allergic reactions to cardiovascular, 
hepatic, renal, neurological and dermatological effects (Pharmar, 2005). Sometimes the 
herb itself is not toxic, however if adulteration occurs during preparation or processing 
(e.g. by heavy metals), toxic effects may be exhibited such as poisoning by the Chinese 
herbal medicine podophyllum (But et al., 1996). A most recent adulterated herbal 
preparation is the decoction leaves of M. speciosa which is known as “ketum juice in the 
northern region of Peninsular Malaysia. While “ketum” was used to increase physical 
endurance and work capacity, there are reports that “ketum juice” was consumed by 
addicts as a substitute of more expensive opiates to manage withdrawal symptoms 
(Assanangkornchai et al., 2007; Vicknasingam & Narayanan, 2009) 
 
“Ketum” is consumed both in unadulterated and adulterated form by mixing 
decoction leaves with cough mixtures, traditional herbs and even synthetic pyrethroid 
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from mosquito coils to add zest but this could result in dreadful consequences . ( 
Bothiphon et al., 2009; Assanangkornchai et al., 2007) . 
In another instance, Zingiber officinale, Piper longum and P. nigrum were used 
in equal parts as Ayurvedic drug for the treatment of respiratory disorders, skin diseases, 
fat metabolism disorders and filariasis. However biochemical studies indicated that P. 
longum and P. nigrum considerably enhanced the bioavailability of bioactive principles 
in other medicines (Handa., 1998; Atal et al., 1981). As such the merits of herbal 
medicines needs further exploration in view of their possible synergistic, additive and/or 
antagonistic effects which may result as different components interact. On the other 
hand it is interesting to note that in ethnophamacology research the practical applications 
and contribution can be viewed variably. Some researchers suggest that the use of 
natural compounds in biomedical and synthetic design of compounds modeled on 
natural products could move forward ethnopharmocologic research in the areas of 
biomedicine therapeutics global health (Akerele, 1987; Oyeneye, 1985; Farnsworth, 
1993; Phillippson & Anderson, 1989).  
In developing nations over 80% of the people, particularly rural populations, rely 
on medicinal plants as part of their primary health care where biomedicines are difficult 
to obtain (Farnsworth, 1993). The use of plants with medicinal values according to 
original and biomedical standards can be considered in lieu of comparably effective 
pharmaceuticals. Licorice (Glycyrrhiza glabra), myrrh (Commiphora species) and 
poppy capsule latex (Papaver somniferum) are plants first reported for such a practice 
.Morphine, codeine, noscapine (narcotine) and papaverine are still clinically used 
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chemical entities derived from opium plant, P. somniferum (Newman et al., 2000). This 
P. somniferum plant has a narcotic property which mainly affects the central nervous 
system (CNS) function and their use as potent pain killers for severe pain has made this 
plant a basis for clinical use drug. However addiction is a major side effect of using such 
drugs (Vetulani, 2001). At present choice of drugs that are proven to be as good as 
morphine for chronic pain management are very limited. Another psychoactive 
compound with good analgesic effect and potential in treating neurological illnesses is 
cannabinoid derived from Cannabis sativa (Watts, 2004; Fernadez-Ruiz et al., 2007).  
However its narcotic, addictive and high adverse effects has limited its use and 
thus made it illegal in most countries. The cannabis plant is well known as marijuana, 
ganja and has many other street names and is widely abused as a recreational drug 
(Watts, 2006). Other alternatives to morphine drugs such as nalbuphine, pentazocine and 
butharphanol are clinically available but their actual analgesic properties remain 
disputed (Science Daily, 2000). Other specific plants such as Ephedra or Ma huang 
(Ephedra spp), which are good nasal decongestants regularly used by the public and 
have direct and indirect effects on the central nervous system, can also stimulate CNS 
side effects from nervousness to imsomnia; Valerian (Valeriana officinalis L.) which has 
long use and a reputation as a sleep aid and a mild tranquiliser has also been shown to 
produce CNS depression (Tyler, 1999). Gingko (Gingko biloba L.) a breakthrough herb 
in the late 1990‟s, was found to be effective in improving cognitive performance and 
social functioning of demented patients, with a lower incidence of side effects; St. 
John‟s Wort (Hypericum perforatum L.), a well-liked herbs in the U.S. is shown to be 
useful in treating mild to moderate depression states; kava (Piper methysticum G. Forst) 
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is effective in treating conditions such as nervous anxiety, stress and restlessness due to 
its narcotic-like effects and devoid of addictive properties. 
There are many more drugs derived from plants, which are successfully 
established as pharmaceuticals which is not covered in this section. Scientific research in 
ethnomedicine is ongoing and is growing rapidly especially in countries like Malaysia 
which has an abundance of natural resources. One of the plants which require immediate 
attention is M. speciosa . It is widely abused for its narcotic-like effects when smoked, 
chewed or taken in its decocted form known as “Air Ketum”. Despite being widely 
abused there are also numerous reports on its medicinal values such as anaesthetic, 
antinociceptive, analgesic and psychostimulant effects (Jansen & Prast 1988; Macko et 
al., 1972 ; Matsumoto et al., 1996 ; Perry, 1980; Tsuchiya et al., 2002). M. speciosa leaf 
are known for its rich alkaloid chemical constituents and MG is the main alkaloid 
constituent of the leaf, responsible for many of the plant‟s pharmacological effects. One 
the other hand the presence of chemical constituents other than alkaloids is not well 
documented to explain claims on the anti-infective properties of M. speciosa leaf. In this 
thesis a portion of work was undertaken to determine the presence of flavonoids and 
polyphenols chemical constituents in M. speciosa leaf and their possible antimicrobial 
and antioxidant activities were investigated as well. 
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2.2 The plant M. speciosa Korth 
2.2.1 Description of the plant M. speciosa  
M. speciosa  Korth is an indigenous tropical herb plant belonging to the family of 
Rubiaeceae (Coffee family) and is found mainly in Southeast Asia countries such as 
Malaysia, Thailand, Myanmar etc. In Malaysia it is commonly known as „ketum‟, biak 
or „biak-biak‟ and is native in the northern and west coast part of Peninsular Malaysia. 
In Thailand, this plant is named as „kratom‟, „thom‟, ‟kakuam‟ or „ithang‟ but globally 
this plant is recognized as „  kratom‟. The genus of this plant „Korth‟ is named after a 
botanist William Korthal who found the stigma of its flower resembling a bishop‟s mitre 
(Shellard, 1974). This plant is a large leafy tree, which can grow up to 15 metres tall. 
The leaves can grow over 5-7 inches long and 3-4 inches wide and dark green in colour 
with yellowish flowers (Shellard, 1974) (Figure.2.1A and B). This plant has two types 
which can be distinguished by the leaves with either red or white-greenish petiole (vein). 
The leaves with petiole (vein) white-greenish were suggested to have stronger effects 
(Suwarnlet, 1975; Murple, 2006). In this dissertation white-greenish vein type of M. 
speciosa leaves were used for pharmacological evaluation. 
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Figure 2.1 A: Young plant of M. speciosa  Korth. The image was taken from 
http://www.entheology.org.15
th
 July 2010 
 
 
Figure.2.1 B: The branch of M. speciosa  Korth leaves with flowers. The image was 
taken from http://www.erowid.org. 15
th
 July 2010 
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2.2.2 Phytochemistry of M. speciosa  
MG is the major alkaloid present in the leaves of this plant (Figure 2.2A). The 
name mitragynine was given by Field who repeated the isolation in 1921 which was first 
done by Hooper (Shellard, 1974). To date, over 25 alkaloids have been isolated and 
chemically elucidated especially from the leaves of the young plant (Houghton & Ikram, 
1986). Among the well-studied alkaloids, apart from MG, which are present in 
Malaysian plants are, 3,4-dehyromitragynine, mitragynaline, corynantheidaline, 
mitragynalinic acid and corynantheidalinic acid (Houghton et al., 1991; Takayama, 
2004), while other found alkaloids are speciogynine, speciociliatine, paynanthiene and 
newly 7-hydroxymitragynine (Figure 2.2 B) (Ponglux et al., 1994; Takayama, 2004); 
MG is the dominant constituent of this plant and constitute more or less 0.2% by weight 
in each kratom leaf and approximately 17 mg in 20 leaves (Grewal, 1932b; Suwanlert, 
1975). Within each country geographical location and season, there is a quantitative 
difference in alkaloid content (Shellard, 1974). The alkaloid content of the leaves of M. 
speciosa  has been reported as approximately around 0.5% to 1.5% in leaf. The leaf 
weigh approximately about 1.7 grams fresh or 0.43 grams dried (Suwanlert,1975). It was 
reported that the Thai and Malaysian plant had the alkaloids mitragynine, speciogynine, 
speciociliatine, paynantheine and 7-hydroxymitragynine in common. In both plants, 
mitragynine was the most abundant alkaloid, but in Thailand the total alkaloid was 66% 
whereas it was only 12% in the Malaysian species (Takayama, 2004). This proofs that 
the content of the alkaloids varies between countries and also the season of the plant 
(Shelard, 1974). 
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(A)  
 
(B)  
Figure.2.2 A) Chemical structures of mitragynine (MG), and B) its congener, 7-
Hydroxymitragynine present in the leaves of M. speciosa Korth. 
 
16 
 
2.2.3 Biological activity. 
M. speciosa Korth plant especially its leaves have been consumed since ancient 
times, where village people such as farmers and labourers chew the fresh leaves, smoke 
the dry leaves or drink as a tea suspension (Jansen & Prast, 1988) or even eat it in the 
form of pellets, for stimulant effects to endure the load of tough labor under the burning 
sun. The leaves and the bark of this plant have been reported for its opium like 
properties and a cure for opium habit (Shellard, 1974; Jansen & Prast (1988). In addition 
the use of kratom as a wound poultice, cure for fever and as a suppressor of the opiate 
withdrawal syndrome has been recorded (Burkill, 1930.) In humans this plant exerts a 
stimulant effect at low doses and sedative and analgesic effects at the higher doses 
suggesting the presence of dual opioid properties (Grewal, 1932b; Suwarnlet, 1975). 
Similar effects have also been observed in animal models as reported by Macko et al., 
(1972).  
Pharmacology activities of kratom and its dominant alkaloid, MG have long been 
reported and reviewed since the 1970‟s. In rodents, upon oral, subcutaneous and 
intraperitoneal administration MG was reported to exert antinociceptive and anti-tussive 
effects (Macko et al., 1972). The crude methanol (MeOH) extract of Thai kratom was 
used in in vitro assay (twitching contraction induced by electric stimulation of guinea-
pig ileum preparation) in which the opioid antagonist, naloxone successfully inhibited 
the contraction, implying that the crude extract is an opioid agonist (Takayama, 2004; 
Watanabe et al., 1992). Several in vitro and in vivo studies followed and support the 
analgesic properties of both crude extract and MG such as reported by Matsumoto et al., 
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(1996), Watanabe et al., (1997) and Idid et al., (1988). Crude extract and MG were also 
reported to successfully act mainly via supraspinal μ, δ and κ opioid receptors (Tsuchiya 
et al., 2002; Tohda et al., 1997; Thongpradichote et al., 1998) in various in vitro and in 
vivo studies. Recently, a minor constituent of this plant and congener for MG, 7-
hydroxymitragynine was found to potently exhibit antinociceptive activities via opioid 
receptors, mainly μ-receptors in in vitro studies, which interestingly showed 13-fold and 
46-fold higher activity than morphine and MG respectively. This promising finding is 
further supported by an in vivo study in mice, which again showed higher 
antinociceptive activity than morphine (Matsumoto & Horie, 2004). Based on these 
findings, it was claimed that 7-hydroxymitragynine could be the active principle for the 
antinociceptive effects exerted by this plant (Takayama, 2004). 
It was reported that chewing the leaves has greater effect for lower doses of MG 
properties (Grewal, 1932b) and neuropsychiatric effects could be achieved within 5 to 
10 minutes post consumption and would last up to 1 hour (Grewal, 1932b; Suwarnlet, 
1975). In in vivo studies, it was reported that MG doses as high as 920 mg/kg have been 
administered without overt clinical effect (Macko et al., 1972). With regards to the 
clinical use in humans, the doses for the stimulant effects, the antinociceptive events and 
the toxicity effects are yet to be fully established (Babu et al., 2008). Some tolerance 
effects have been reported among users and clinical effects such as antitussive, 
antinociceptive and anti-diarrhoeal effects of MG use was also described to be similar to 
codeine (Suwarnlet, 1975; Jansen & Prast, 1988). Besides its analgesic and narcotic-like 
pharmacological effects, several side effects have been reported among kratom users 
such as nausea, vomiting, diarrhoea, nystagmus and tremor (Grewal, 1932b) and for 
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chronic users anorexia, weight loss, hyperpigmentation and prolonged sleep were 
observed (Suwanlert, 1975). Opioid abstinence syndrome such as irritability, yawning, 
rhinorrhoea, myalgias, diarrhoea and arthralgia were reported in some kratom users thus 
suggesting possible addictive properties of this plant (Thuan, 1957; Suwarnlet,1975; 
Babu et al., 2008). Recently, major concern has arisen in Malaysia as the narcotism 
properties of this plant have attracted the misuse of it by drug addicts as an opium 
substitute.  
Due to this, an act was passed in 2004 (under the Poison Control Act 1952) 
which makes the possession of any form of the plant by the public illegal. It is an 
offence under Section 30(3) of the Poisons Act 1952 to possess and sell ketum leaves in 
Malaysia. In fact, Thailand has legislated this plant since 1946. Australia also followed 
to criminalise the possession of this plant in 2005. However, in other parts of the world, 
kratom is currently not scheduled. The availability of kratom over the internet has 
attracted many Western populations to use the plant as self-treatment in opioid 
withdrawal and chronic pain (Boyer et al., 2007). Though past reports described the 
medical use of this plant to replace morphin in addicts‟ detoxification and treatment 
programme, the pharmacological profiles of this intriguing alkaloid MG and the kratom 
leaf have yet to be fully studied. It is also important to note that the leaves contain 
several other substances that may modify the effects of the drug (Thuan, 1957).  
The way that MG work in the human body is not clearly defined and this 
bioactive that account for effects and the mechanisms of actions are generally not well 
researched and understood owing to limited analytical tools to detect and assay MG in 
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biological fluids. Therefore the core research in this thesis undertook prime work on 
developing a simple rapid HPLC-UV method for assay of MG in plasma for application 
in detailed MG pharmacokinetic studies in rats. 
2.3 Method Development and Validation in HPLC 
2.3.1 Introduction 
Qualitative methods of analysis provide basic information about the composition 
of a sample and perform quite simple chemical reactions to identify the analytes it 
contains (Burriel et al., 1989). Quantitative methods of analysis provide information not 
only about the composition but also about the concentration of the analytes present in 
the sample and, generally speaking, they often require more complex analytical 
techniques to obtain more accurate and reliable information about the sample. 
Quantitative and qualitative study of substances in biological fluids such as plasma, 
serum, tissue or urine is indispensable in bioanalytical chemistry. Pharmacokinetics, 
bioequivalence and bioavailability studies understanding largely depend on this 
significant analytical study (Bressolle et al., 1996). The main analytical phases are 
method development, validation and method appliance. 
The vast development of analytical methods among the global community has 
marked acceptance internationally. As such, to declare a universal level of excellence, 
the use of validated methods is crucial (Hartmann et al., 1998). In analytical chemistry 
no matter what way the analysis is made it must be checked to distinguish whether it 
works as proposed. Each methodology must be investigated to determine the extent to 
which atmosphere, matrix, or technical variables can affect the assessment of analyte in 
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the matrix from the time of collection up to the time of analysis. Analytical methods are 
generally used for product improvement, product research, procedure control and for 
chemical quality control reasons. In chromatographic or spectroscopic analysis each of 
their procedure, has its own uniqueness and shortage that has to be addressed. 
2.3.2 Method development 
An analytical method includes procedures for analysis of an analyte in biological 
matrices such as blood, plasma, serum etc starting from time of sample collection, 
processing and storing (Shah et al., 1992). Bioequivalence and pharmacokinetics 
assessment studies primarily rely on a quantitative determination of analyte and 
metabolites in biological fluids with good reproducible and accuracy of data (Shah et al., 
2000). 
Assessment and optimization of the different steps in sample preparation, 
detection, chromatographic separation, and quantification are crucial steps in method 
development. The selection of instruments (eg; HPLC, GC, LCMS) that are suitable for 
the analysis of compound(s) of interest is first to be considered. After that the choice of 
analytical column, detector, and selection of appropriate mobile phase are essential for 
the analytical method to be thoroughly developed and optimized prior to validation. The 
objective of validation of analytical procedure is to demonstrate that the method is 
suitable for the intended purpose. An efficient extraction procedure which gives the 
maximum recovery without endogenous interference with adequate accuracy and 
precision are preferred in assay development. In accordance to FDA Guidance, the 
recovery of an analyte is defined as “the extraction efficiency of an analytical process, 
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reported as a percentage of the known amount of an analyte carried through the sample 
extraction and processing steps of the method. The selection of internal standard with 
similar chromatographic properties to analyte of interest is crucial in method 
development. At times an internal standard is added at a known concentration directly to 
an analytical sample to assist in quantification. The amount of analyte present is then 
determined relative to the internal standard as a calibrant (Causon, 1997; Karnes et al., 
1991). 
2.3.3 Method validation 
Method validation is a process involving method documentation and continued 
application of the analytical method for the intended purpose. (Bruce et al., 1998 ; 
Hartmann et al., 1998). The validation procedure includes assessment of fundamental 
validation parameters such as precision accuracy, recovery, selectivity, sensitivity, 
stability and the calibration curve (Shah et al., 1992). Validation exercise demonstrates 
that the analytical method is repeatable, specific and suitable for its intended application 
and in the case of biomedical application it is crucial to support the registration of a new 
drug or a new formulation of an existing one (Wieling et al., 1996; Causon, 1997). Both 
the HPLC-UV methods for assay of MG in plasma and plant extracts described in this 
dissertation were optimized and validated using the above mentioned parameters prior to 
their application in pharmacokinetics and pharmacological studies. This is to ensure the 
data generated are reliable and valid for a useful pharmacokinetic evaluation of MG in 
animal model and to standardize M. speciosa extracts for pharmacological studies. 
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2.3.3(a) Full Method validation and Partial Method validation 
Full validation is performed when developing and applying a bioanalytical 
procedure for the first time for its use in pharmacokinetic, bioavailability, and 
bioequivalence and drug interaction studies in a new drug application (NDA) (Shah et 
al., 2000). Partial validations are carried out when there is a departure or modification in 
the present validated bioanalytical method. Partial validation could range from one intra-
assay and precision determination to an almost full validation. Modification in analytical 
methodology, transfer of bioanalytical method between laboratories or analyst, change 
of matrix within species, change of species within matrix will result in partial validation 
(Shah et al., 2000; FDA, 2001). The choice of parameter to be revalidated is determined 
by the constraint likely to be affected by the change made to the bioanalytical method. In 
this thesis MG HPLC analytical method was developed and validated in human plasma 
for application in rat pharmacokinetic studies. Partial validation using rat plasma was 
carried out for inter-day and intra-day precision determination. 
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2.3.3(b) Cross validation 
When two or more bioanalytical methods are used to generate data within the 
same study or across different studies cross validation of analytical parameters are 
required. In a cross validation the original validated bioanalytical method serves as the 
reference and the revised bioanalytical method is the comparator (Shah et al.,2000; FDA 
2001). 
2.3.4 Limits of detection and quantification (LLOD and LLOQ) 
 
US pharmacopoeia (USP) defines the limit of detection (LOD) as the lowest 
analyte concentration in a sample which can be detected but not necessarily quantified. 
The lowest limit of quantification (LLOQ) is defined as the lowest analyte concentration 
in a sample that can be measured, with precision and accuracy within the acceptable 
range. (Krull & Swartz, 1998). Signal-to-noise ratio is defined as the ratio between a 
signal (meaningful peak) and the background noise. Using visual inspection approach, 
the signal is calculated from the base line to peak summit and divided by the peak-to-
peak noise, which is determined from the blank plasma injection. Signal-to-noise ratios 
of approximately 2:1 or 3:1 and 10:1 were used in estimating the detection limit and 
quantification limit respectively (Figure3.0). Alternatively LOD and LOQ are calculated 
in terms of the mean and standard deviation (SD) from a series of blank samples (ie., 
LOD and LOQ = mean ± kSD). In estimation of LOD, k is equal to six. For LOQ k is 
equal to ten when maximum allowed SD of 10% is desired (Green et al., 2002). 
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Figure 2.3: Limit of detection and limit of quantitation via signal to noise( ICH,1996) 
2.3.5 Calibration curve 
A calibration curve shows the relation between the analyte concentration in the 
sample and the detected response. To define adequately the relationship between 
response and concentration it is crucial to use a sufficient number of calibration points 
(n=6) (Shah et al.,1992). Linear regressions of the response (peak height/area(Y)) of the 
analyte are plotted against the corresponding analyte concentration (X) to establish the 
slope, intercept and coefficient of correlation. The difference between the observed y-
value and fitted y-value is called a residual. In linear regression analysis one of the 
assumptions is that the calculated residuals are independent, are normally distributed and 
have equal variance, which is termed as homoscedasticity or if otherwise termed as 
heteroscedasticity. If the variance is not equal, then the weighted regression may be 
performed. The most appropriate weighting factor is the inverse of the variance of the 
standard, although 1/x, 1/x2, 1/y and 1/y2 (x = concentration and y = response) are 
suitable approximations. However, the selection of the right statistical model for the 
evaluation of the calibration curve must be scientifically justified if regression type is 
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changed without formal revalidation during sample analysis (Lang & Bolton, 1991; 
Chow, 2009). 
 It is a standard practice in an analysis that a standard curve should cover the 
entire range of the concentration of the unknown samples. It is not recommended to 
estimate the concentration of the unknown by extrapolation of the standard curve below 
the lower or higher calibration points. As an alternative, it is suggested that the standard 
curve be re-determined or sample re-assayed after dilution (Shah et al., 1992). Dadgar et 
al., (1995), in his guidelines suggested several exclusion criteria for omitting calibration 
points provided at least seven non-zero calibration points are used to construct 
calibration curve. At least up to two non-zero standards may be removed from the 
calibration for the following valid reasons : (i) loss of sensitivity in processed samples, 
(ii) sample loss during processing or (iii) poor chromatography peaks during analysis . 
Acceptability of the linearity data is often judged by examining the correlation 
coefficient and y-intercept of the linear regression line for the response versus 
concentration plot. A correlation coefficient of > 0.999 is generally considered as 
evidence of an acceptable fit of the data to the regression line (Green, 1996). 
 
 
  
